Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer

BackgroundMore than half of patients with colorectal cancer (CRC) present with metastatic disease or develop recurrent disease on first-line and second-line options. Treatment beyond the second line remains an area of unmet need for patients with progressive or recurrent disease.MethodsWe retrospect...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Emaan Haque, Ibrahim N. Muhsen, Abdullah Esmail, Godsfavour Umoru, Charisma Mylavarapu, Veronica B. Ajewole, Maen Abdelrahim
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Subjects:	regorafenib 5-FU metastatic colorectal cancer CRC fluorouracil (3385)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.992455/full